Skip to main content
. Author manuscript; available in PMC: 2023 Nov 24.
Published in final edited form as: Gynecol Oncol. 2022 Sep 30;167(2):213–225. doi: 10.1016/j.ygyno.2022.09.019

FIGURE 2:

FIGURE 2:

FIGURE 2:

FIGURE 2:

FIGURE 2:

Correlation with alterations in DNA damage response genes and cell cycle regulators; Cohort 1: Platinum resistant, BRCA-wildtype with ≥3 prior lines of therapy; Cohort 2: Platinum resistant, BRCA-wildtype with <3 prior lines of therapy; Cohort 3: Platinum resistant, BRCA-mutated with prior PARP inhibitor therapy; Cohort 4: Platinum refractory with any number of prior lines of therapy. The copy number is indicated in the cells for genes with amplification.

Abbreviations: BRCA, breast cancer gene.

Notes: cyclin E1 H-score is also included; Several patients had a >30% decrease in target lesions, but the PRs were not confirmed and therefore per RECISIT 1.1 the confirmed best overall response is SD. Similarly, several patients had <20% increase in target lesions but met another criterion for progressive disease (eg. detection of a new lesion, or unequivocal progression of a non-target lesion).